Regent Peak Wealth Advisors LLC Invests $204,000 in Stryker Co. (NYSE:SYK)

Regent Peak Wealth Advisors LLC bought a new stake in shares of Stryker Co. (NYSE:SYK) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 567 shares of the medical technology company’s stock, valued at approximately $204,000.

Several other institutional investors also recently bought and sold shares of the company. Parnassus Investments LLC acquired a new stake in Stryker in the third quarter worth about $762,798,000. International Assets Investment Management LLC raised its position in shares of Stryker by 66,967.5% in the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock valued at $308,433,000 after purchasing an additional 852,496 shares during the last quarter. RTW Investments LP acquired a new stake in Stryker in the 3rd quarter worth approximately $143,392,000. American Century Companies Inc. grew its position in Stryker by 287.6% during the 2nd quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company’s stock worth $172,033,000 after purchasing an additional 375,166 shares during the last quarter. Finally, State Street Corp increased its stake in Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock valued at $5,279,788,000 after purchasing an additional 316,404 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of SYK traded down $5.24 during trading hours on Tuesday, hitting $356.12. 799,096 shares of the stock were exchanged, compared to its average volume of 922,216. The stock’s 50-day moving average price is $375.33 and its two-hundred day moving average price is $357.33. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company has a market cap of $135.76 billion, a price-to-earnings ratio of 38.17, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. Stryker Co. has a 12-month low of $294.34 and a 12-month high of $398.20.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.46 earnings per share. Research analysts expect that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.94%. Stryker’s dividend payout ratio is 36.01%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on SYK shares. JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Citigroup lifted their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday. Evercore ISI lifted their target price on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $425.00 price target on shares of Stryker in a research report on Tuesday. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $405.80.

Insider Activity at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.